Elos Medtech commits to the global orthopaedic market
Orthopaedics is a strategically important business segment for Elos Medtech and today we announce our commitment to focus on and grow this market. We will dedicate resources and develop a strong cross-site platform to further build our competence and capacity in support of our global customers.
Elos Medtech announces that Jodie Gilmore, Managing Director Elos Medtech Onyx, will take up a new role as Orthopaedic Business Director and lead our global orthopaedic strategy as we continue our journey focusing entirely on the medical device industry.
“Elos Medtech is excited to highlight orthopaedics as one of the primary areas of focus and to execute on our market specific strategies. This is a natural step toward achieving our growth targets and capitalizing on our 2015 acquisition of Onyx Medical”, says Jan Wahlström, CEO and President.
“I am truly passionate about orthopaedics and have focused my energy here for more than 20 years”, says Jodie Gilmore. “I am thrilled to champion this market within Elos Medtech and leverage our incredible group capabilities for the benefit of our orthopaedic customers.” Jodie Gilmore will remain in Memphis and continue as the Managing Director of the Elos Medtech Onyx site.
Elos Medtech is one of the leading development and production partners for medical technology products and components in the world, such as dental and orthopaedic implants and instruments. The operations are conducted at facilities in Sweden, Denmark, China and the US. Customers are internationally active medical technology companies.
Elos Medtech employs more than 500 people worldwide and generates revenue that exceeds MSEK 550. Elos Medtech has been traded on NASDAQ Stockholm AB since 1989. The Elos Medtech B share is classified as a Health Care company on the Small Cap list.
Gothenburg, November 14, 2017
Elos Medtech AB (publ)
For further information, contact:
This is the type of information that Elos Medtech AB (publ) is obliged to publish in accordance with the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was issued for publication by the contact persons stated above on November 14, 2017, at 08.00. (CET).
For additional information about the Elos Medtech Group, visit www.elosmedtech.com